No Data
No Data
Alnylam Delivers Q1 Surprise, Analysts Highlight Amvuttra Momentum, Limited Tariff Risk
A Quick Look at Today's Ratings for Alnylam Pharmaceuticals(ALNY.US), With a Forecast Between $287 to $371
Apple To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Friday
Chardan Capital Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $325
Alnylam Pharmaceuticals Analyst Ratings
Alnylam Pharmaceuticals Reports Strong Start to 2025